

Marco Bandini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3095434/publications.pdf>

Version: 2024-02-01

150
papers

2,580
citations

257450

24
h-index

289244

40
g-index

154
all docs

154
docs citations

154
times ranked

2980
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. <i>European Urology Focus</i> , 2022, 8, 491-497.	3.1	13
2	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 10.e1-10.e6.	1.6	20
3	Challenging the dogma of 6 steps for anastomotic urethroplasty in posterior urethral stricture: introducing step 3a. <i>World Journal of Urology</i> , 2022, 40, 1277-1278.	2.2	4
4	Re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? <i>Eur Urol</i> 2020;78:e218â€“9. <i>European Urology</i> , 2022, 81, e14-e15.	1.9	0
5	Graft Plus Fasciocutaneous Penile Flap for Nearly or Completely Obliterated Long Bulbar and Penobulbar Strictures. <i>European Urology Open Science</i> , 2022, 35, 21-28.	0.4	5
6	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 227-236.	1.9	3
7	Comprehensive analysis of paediatric pelvic fracture urethral injury: a reconstructive centre experience. <i>BJU International</i> , 2022, 130, 114-125.	2.5	3
8	Dorsal approach for double-face bulbar urethroplasty: ventral inlay plus dorsal onlay using Kulkarni one-side dissection. <i>International Urology and Nephrology</i> , 2022, 54, 1039.	1.4	0
9	A global approach to improving penile cancer care. <i>Nature Reviews Urology</i> , 2022, 19, 231-239.	3.8	28
10	Mucosalâ€“sparing augmented nonâ€“transected anastomotic (<sc>MsANTA</sc>) urethroplasty: a step forward in <sc>ANTA</sc> urethroplasty. <i>BJU International</i> , 2022, 130, 133-136.	2.5	5
11	How to get involved in clinical research: helpful tips.. <i>Canadian Journal of Urology</i> , 2022, 29, 11024-11026.	0.0	0
12	Common Flaps in Genitourinary Reconstruction. <i>Urologic Clinics of North America</i> , 2022, , .	1.8	0
13	Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. <i>Eur Urol Focus</i> 2020;6:639â€“41. <i>European Urology Focus</i> , 2021, 7, 1506-1507.	3.1	1
14	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. <i>European Urology Oncology</i> , 2021, 4, 802-810.	5.4	22
15	Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 237-245.e2.	1.9	5
16	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2021, 7, 1092-1099.	3.1	4
17	Patient-reported outcomes for typical single cheek harvesting vs atypical lingual, labial or bilateral cheeks harvesting: a single-center analysis of more than 800 patients. <i>World Journal of Urology</i> , 2021, 39, 2089-2097.	2.2	7
18	Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?. <i>European Urology Oncology</i> , 2021, 4, 1006-1010.	5.4	11

#	ARTICLE	IF	CITATIONS
19	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. <i>European Urology Oncology</i> , 2021, 4, 1001-1005.	5.4	23
20	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 829-833.	5.4	20
21	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 48-53.	6.3	30
22	Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer?. <i>European Urology</i> , 2021, 79, 713-716.	1.9	3
23	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. <i>European Urology Oncology</i> , 2021, 4, 121-123.	5.4	5
24	Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. <i>Eur Urol Oncol</i> 2021;4:12-9. <i>European Urology Oncology</i> , 2021, 4, 126.	5.4	0
25	Revolutionizing care for rare genitourinary tumours. <i>Nature Reviews Urology</i> , 2021, 18, 69-70.	3.8	9
26	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e15-235.e21.	1.6	10
27	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 193-201.	3.9	7
28	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110216.	1.3	12
29	SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS506-TPS506.	1.6	8
30	Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting. <i>World Journal of Urology</i> , 2021, 39, 3921-3930.	2.2	14
31	Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. <i>Eur Urol Focus</i> 2020;6:1233-9. <i>European Urology Focus</i> , 2021, , .	3.1	0
32	Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , 2021, , .	5.4	6
33	Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. <i>BJU International</i> , 2021, 128, 607-614.	2.5	10
34	High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?. <i>Current Problems in Cancer</i> , 2021, 45, 100759.	2.0	5
35	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2021, 5, 261-261.	5.4	0
36	Primary Adult Retroperitoneal Sarcoma: A Comprehensive Genomic Profiling Study. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, 216-228.	0.4	1

#	ARTICLE	IF	CITATIONS
37	The Right Instrument for the Right Purpose: Spreading the Use of Small Caliber Ureteroscope for the Inspection of the Male and Female Urethra. <i>Société Internationale D'urologie Journal</i> , 2021, 2, 259-263.	0.4	6
38	The Pros and Cons of "Machination of Medicine" in Genitourinary Oncology Practice. <i>Bladder Cancer</i> , 2021, , 1-5.	0.4	0
39	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021, 80, 149-159.	1.9	17
40	Causal contributors to tissue stiffness and clinical relevance in urology. <i>Communications Biology</i> , 2021, 4, 1011.	4.4	34
41	Dissecting patterns of care in patients with variant histology of bladder cancer and lymph node invasion. <i>Société Internationale D'urologie Journal</i> , 2021, , 282-298.	0.4	0
42	Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 838.e7-838.e13.	1.6	3
43	Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. <i>European Urology</i> , 2021, 80, 319-322.	1.9	24
44	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 734.e11-734.e17.	1.6	4
45	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , 2021, 80, 507-515.	1.9	27
46	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 969-969.	0.4	0
47	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 631-641.	1.6	7
48	Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. <i>Journal of Urology</i> , 2021, 206, 960-969.	0.4	8
49	Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 37-37.	1.6	2
50	Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. <i>European Urology Oncology</i> , 2020, 3, 631-639.	5.4	4
51	Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 73-79.	5.4	29
52	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 204-209.	1.6	8
53	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , 2020, 77, 439-446.	1.9	228
54	Prevalence, assessment and surgical correction of penile curvature in hypospadias patients treated at one European Referral Center: description of the technique and surgical outcomes. <i>World Journal of Urology</i> , 2020, 38, 2041-2048.	2.2	12

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant chemotherapy for lymph node-positive penile cancer. <i>Current Opinion in Urology</i> , 2020, 30, 218-222.	1.8	12
56	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020, 77, 636-643.	1.9	75
57	Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. <i>European Urology Oncology</i> , 2020, 3, 474-480.	5.4	15
58	Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. <i>Eur Urol</i> 2020;77:55-65. <i>European Urology</i> , 2020, 78, e75-e76.	1.9	0
59	A risk calculator predicting recurrence in lymph node metastatic penile cancer. <i>BJU International</i> , 2020, 126, 577-585.	2.5	12
60	Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. <i>Eur Urol</i> 2020;77:636-43. <i>European Urology</i> , 2020, 77, e159-e160.	1.9	1
61	Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. <i>European Urology</i> , 2020, 78, 489-491.	1.9	8
62	The new era of precision urobiome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 693-694.	1.6	1
63	Targetable gene fusions and aberrations in genitourinary oncology. <i>Nature Reviews Urology</i> , 2020, 17, 613-625.	3.8	35
64	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-negative penile squamous cell carcinoma. <i>BJU International</i> , 2020, 125, 867-875.	2.5	15
65	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 701-710.	1.9	128
66	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e543-e556.	1.9	22
67	Risk calculator for prediction of treatment-related urethroplasty failure in patients with penile urethral strictures. <i>International Urology and Nephrology</i> , 2020, 52, 1079-1085.	1.4	8
68	Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in children with proximal hypospadias. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 1029-1041.	1.5	5
69	Surgical treatment of bulbar urethral strictures: tips and tricks. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 511-518.	1.5	13
70	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 967-968.	0.4	0
71	Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. <i>European Urology Focus</i> , 2019, 5, 807-814.	3.1	22
72	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , 2019, 76, 425-429.	1.9	15

#	ARTICLE	IF	CITATIONS
73	Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e939-e945.	1.9	9
74	Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. <i>Canadian Urological Association Journal</i> , 2019, 14, E84-E93.	0.6	5
75	Validation of the GGrade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 13218.	3.3	14
76	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. <i>European Urology Oncology</i> , 2019, 2, 541-548.	5.4	31
77	Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis. <i>Surgical Oncology</i> , 2019, 28, 201-207.	1.6	18
78	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e602-e611.	1.9	17
79	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2â€“4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , 2019, 2, 248-256.	5.4	11
80	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2019, 14, E173-E179.	0.6	1
81	Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 629-635.	1.8	5
82	Nomograms in urologic oncology, advantages and disadvantages. <i>Current Opinion in Urology</i> , 2019, 29, 42-51.	1.8	27
83	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. <i>European Urology</i> , 2019, 75, 817-825.	1.9	17
84	Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e97-e103.	1.9	7
85	Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e130-e139.	1.9	23
86	Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. <i>World Journal of Urology</i> , 2019, 37, 1305-1313.	2.2	13
87	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 72-78.e4.	1.9	10
88	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. <i>European Urology Focus</i> , 2019, 5, 381-388.	3.1	12
89	The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. <i>European Urology Focus</i> , 2019, 5, 399-406.	3.1	19
90	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. <i>European Urology Focus</i> , 2019, 5, 467-473.	3.1	21

#	ARTICLE	IF	CITATIONS
91	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. <i>European Urology Focus</i> , 2019, 5, 488-496.	3.1	41
92	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. <i>European Urology Focus</i> , 2019, 5, 449-456.	3.1	11
93	UICC and AJCC 8th edition tumor-nodes-metastasis (TNM) classifications for patients treated with radical prostatectomy: reliable but not infallible prognostic tools. <i>Annals of Translational Medicine</i> , 2019, 7, S41-S41.	1.7	3
94	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 716-716.	0.4	0
95	Prevalence and surgical management of pubic hypertrophy in hypospadias patients: results from a high-volume surgeon. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 1238-1248.	1.5	2
96	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>Prostate</i> , 2018, 78, 469-475.	2.3	40
97	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 386-393.	3.9	11
98	Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>The Prostate</i> . 2018;1â€7. <i>Prostate</i> , 2018, 78, 692-692.	2.3	2
99	Survival benefit of local versus no local treatment for metastatic prostate cancerâ€”Impact of baseline PSA and metastatic substages. <i>Prostate</i> , 2018, 78, 753-757.	2.3	27
100	Local treatment for metastatic prostate cancer: A systematic review. <i>International Journal of Urology</i> , 2018, 25, 390-403.	1.0	37
101	A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. <i>Radiotherapy and Oncology</i> , 2018, 127, 318-325.	0.6	13
102	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 239.e9-239.e15.	1.6	6
103	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 176-183.	1.9	16
104	Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 377-387.	2.4	7
105	Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged â‰¥50 years: a population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 71-77.	3.9	13
106	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 425-438.	3.1	17
107	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 81.e17-81.e24.	1.6	18
108	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 1399-1407.	2.2	16

#	ARTICLE	IF	CITATIONS
109	Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. <i>World Journal of Urology</i> , 2018, 36, 1417-1422.	2.2	11
110	Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer. <i>BJU International</i> , 2018, 121, 421-427.	2.5	24
111	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , 2018, 36, 7-13.	2.2	23
112	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. <i>World Journal of Urology</i> , 2018, 36, 51-57.	2.2	16
113	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT₂ non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , 2018, 121, 383-392.	2.5	30
114	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. <i>BJU International</i> , 2018, 121, 592-599.	2.5	32
115	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. <i>International Urology and Nephrology</i> , 2018, 50, 71-78.	1.4	37
116	Anastomotic leaks and catheter time after salvage robot-assisted radical prostatectomy. <i>Translational Andrology and Urology</i> , 2018, 7, S141-S143.	1.4	4
117	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. <i>European Urology Oncology</i> , 2018, 1, 169-175.	5.4	16
118	The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. <i>European Urology Oncology</i> , 2018, 1, 215-222.	5.4	12
119	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. <i>British Journal of Cancer</i> , 2018, 119, 1552-1556.	6.4	10
120	The effect of race on survival after local therapy in metastatic prostate cancer patients. <i>Canadian Urological Association Journal</i> , 2018, 13, 175-181.	0.6	2
121	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 56, 118-125.	1.9	19
122	Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. <i>International Journal of Urology</i> , 2018, 25, 929-936.	1.0	3
123	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 54, 112-118.	1.9	13
124	Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. <i>Journal of Endourology</i> , 2018, 32, 701-709.	2.1	11
125	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. <i>European Urology Oncology</i> , 2018, 1, 314-320.	5.4	19
126	Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. <i>European Urology Oncology</i> , 2018, 1, 346-351.	5.4	7

#	ARTICLE	IF	CITATIONS
127	Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018, 74, 693-696.	1.9	19
128	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2018, 12, E325-30.	0.6	13
129	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018, 12, 173-80.	0.6	16
130	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 160-168.	5.4	15
131	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. <i>Journal of Endourology</i> , 2018, 32, 621-629.	2.1	8
132	Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 376-384.e1.	1.9	27
133	Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 365.e1-365.e7.	1.6	9
134	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e603-e607.	1.9	27
135	Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 1541-1547.	2.2	41
136	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. <i>European Urology</i> , 2017, 72, 632-640.	1.9	165
137	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. <i>European Urology</i> , 2017, 72, 910-917.	1.9	21
138	Obesity and prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 415-421.	1.8	40
139	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2017, 14, 876-882.	0.6	16
140	An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer. <i>Urology Case Reports</i> , 2017, 12, 34-36.	0.3	5
141	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma. <i>World Journal of Urology</i> , 2017, 35, 1899-1905.	2.2	28
142	New surgical approaches for clinically high-risk or metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1013-1031.	2.4	9
143	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. <i>International Urology and Nephrology</i> , 2017, 49, 2143-2149.	1.4	36
144	Salvage surgery for nodal recurrent prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 604-611.	1.8	10

#	ARTICLE	IF	CITATIONS
145	Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. <i>European Urology</i> , 2017, 72, 289-292.	1.9	81
146	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e223-e228.	1.9	5
147	Can the multiphasic computed tomography be useful in the clinical management of small renal masses?. <i>Acta Radiologica</i> , 2017, 58, 625-633.	1.1	5
148	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 669-675.	0.4	55
149	Partial mobilisation of the neurovascular bundle for ventral penile curvature correction: A proof-of-concept study. <i>Journal of Clinical Urology</i> , 0, , 205141582110593.	0.1	1
150	Which are the commonest sites and characteristics of post- transurethral prostate surgery (TPS) strictures in a high-volume reconstructive center?. <i>Journal of Endourology</i> , 0, , .	2.1	2